Paclitaxel in ovarian cancer: how can we make it better?
SA Cannistra
JCO Sep 1 1994: 1743–1744. [PDF]
Vinorelbine: a horse of a different color?
HM Pinedo and CJ Van Groeningen
JCO Sep 1 1994: 1745–1747. [PDF]
	Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study
	JT Thigpen, JA Blessing, H Ball, SJ Hummel, and RJ Barrett
	JCO Sep 1 1994: 1748–1753. [Abstract] [PDF]
	Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors
	EK Rowinsky, DA Noe, DL Trump, EP Winer, VS Lucas, WA Wargin, JA Hohneker, B Lubejko, SE Sartorius, and DS Ettinger
	JCO Sep 1 1994: 1754–1763. [Abstract] [PDF]
	Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer
	M Spielmann, T Dorval, F Turpin, E Antoine, M Jouve, F Maylevin, D Lacombe, J Rouesse, P Pouillart, and T Tursz
	JCO Sep 1 1994: 1764–1770. [Abstract] [PDF]
	Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial
	GC Wishart, D Bissett, J Paul, D Jodrell, A Harnett, T Habeshaw, DJ Kerr, MA Macham, M Soukop, and RC Leonard
	JCO Sep 1 1994: 1771–1777. [Abstract] [PDF]
	Psychosocial adjustment among women with breast cancer stages I and II: six-year follow-up of consecutive patients
	M Omne-Ponten, L Holmberg, and PO Sjoden
	JCO Sep 1 1994: 1778–1782. [Abstract] [PDF]
	Effect of a National Cancer Institute Clinical Alert on breast cancer practice patterns
	TP Johnson, L Ford, RB Warnecke, SG Nayfield, A Kaluzny, G Cutter, D Gillings, E Sondik, and H Ozer
	JCO Sep 1 1994: 1783–1788. [Abstract] [PDF]
	A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology
	RT Chlebowski and LM Lillington
	JCO Sep 1 1994: 1789–1795. [Abstract] [PDF]
	Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators
	KM Taylor, ML Feldstein, RT Skeel, KJ Pandya, P Ng, and PP Carbone
	JCO Sep 1 1994: 1796–1805. [Abstract] [PDF]
	Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial
	RL Souhami, R Rudd, MC Ruiz de Elvira, L James, N Gower, PG Harper, JS Tobias, MR Partridge, AG Davison, and C Trask
	JCO Sep 1 1994: 1806–1813. [Abstract] [PDF]
	Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study
	MB Hazuka, JJ Crowley, PA Bunn, Jr, M O'Rourke, TJ Braun, and RB Livingston
	JCO Sep 1 1994: 1814–1820. [Abstract] [PDF]
	Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study
	H Anderson, B Lund, F Bach, N Thatcher, J Walling, and HH Hansen
	JCO Sep 1 1994: 1821–1826. [Abstract] [PDF]
	Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer
	B Passlick, JR Izbicki, B Kubuschok, W Nathrath, O Thetter, U Pichlmeier, L Schweiberer, G Riethmuller, and K Pantel
	JCO Sep 1 1994: 1827–1832. [Abstract] [PDF]
	Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
	N Masuda, M Fukuoka, S Kudoh, K Matsui, Y Kusunoki, M Takada, K Nakagawa, T Hirashima, H Tsukada, and T Yana
	JCO Sep 1 1994: 1833–1841. [Abstract] [PDF]
	Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup
	D Ornadel, RL Souhami, J Whelan, M Nooy, C Ruiz de Elvira, J Pringle, I Lewis, WP Steward, R George, and J Bridgewater
	JCO Sep 1 1994: 1842–1848. [Abstract] [PDF]
	Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases
	WG Ward, K Mikaelian, F Dorey, JM Mirra, A Sassoon, EC Holmes, FR Eilber, and JJ Eckardt
	JCO Sep 1 1994: 1849–1858. [Abstract] [PDF]
	Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery
	MM Heiss, W Mempel, C Delanoff, KW Jauch, C Gabka, M Mempel, HJ Dieterich, HJ Eissner, and FW Schildberg
	JCO Sep 1 1994: 1859–1867. [Abstract] [PDF]
	Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report
	M Hussain, M Wolf, E Marshall, ED Crawford, and M Eisenberger
	JCO Sep 1 1994: 1868–1875. [Abstract] [PDF]
	Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study
	S Leyvraz, P Pasche, J Bauer, S Bernasconi, and P Monnier
	JCO Sep 1 1994: 1876–1885. [Abstract] [PDF]
	Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma
	CJ Watling, DH Lee, DR Macdonald, and JG Cairncross
	JCO Sep 1 1994: 1886–1889. [Abstract] [PDF]
	Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma
	DR Adkins, D Salzman, D Boldt, J Kuhn, R Irvin, GD Roodman, R Lyons, L Smith, CO Freytes, and CF LeMaistre
	JCO Sep 1 1994: 1890–1901. [Abstract] [PDF]
	Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors
	DR Budman, LN Igwemezie, S Kaul, J Behr, S Lichtman, P Schulman, V Vinciguerra, SL Allen, J Kolitz, and K Hock
	JCO Sep 1 1994: 1902–1909. [Abstract] [PDF]
	Improved survival for patients with AIDS-related Kaposi's sarcoma
	SA Miles, H Wang, R Elashoff, and RT Mitsuyasu
	JCO Sep 1 1994: 1910–1916. [Abstract] [PDF]
	Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation
	B Gordon, A Spadinger, E Hodges, E Ruby, R Stanley, and P Coccia
	JCO Sep 1 1994: 1917–1922. [Abstract] [PDF]
	Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies
	SA Giralt, CF LeMaistre, HM Vriesendorp, BS Andersson, M Dimopoulos, J Gajewski, K Van Besien, R Mehra, D Przepiorka, and I Khouri
	JCO Sep 1 1994: 1923–1930. [Abstract] [PDF]
	Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies
	RA Stahel, LM Jost, T Cerny, G Pichert, H Honegger, A Tobler, E Jacky, M Fey, and E Platzer
	JCO Sep 1 1994: 1931–1938. [Abstract] [PDF]
	Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study
	VJ Land, JJ Shuster, WM Crist, Y Ravindranath, MB Harris, RA Krance, D Pinkel, and DJ Pullen
	JCO Sep 1 1994: 1939–1945. [Abstract] [PDF]
	Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity
	CF Stewart, SD Baker, RL Heideman, D Jones, WR Crom, and CB Pratt
	JCO Sep 1 1994: 1946–1954. [Abstract] [PDF]
	Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies
	CT Tan, N Wollner, T Trippett, E Goker, WP Tong, A Kheradpour, PA Meyers, KM VanSyckle, L Guarino, and Y Elisseyeff
	JCO Sep 1 1994: 1955–1962. [Abstract] [PDF]
	Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood
	PT Maluf, V Odone Filho, LM Cristofani, JL Britto, MT Almeida, E Pontes, JG Maksoud, and A Manissadjian
	JCO Sep 1 1994: 1963–1968. [Abstract] [PDF]
	Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study
	PD Sadowitz, R Dubowy, A Souid, BH Pollock, H Weinstein, RT Parmley, WP Bowman, V Land, T Vats, and C Pratt
	JCO Sep 1 1994: 1969–1973. [Abstract] [PDF]
	Chronic lymphocytic leukemia: an updated review
	GB Faguet
	JCO Sep 1 1994: 1974–1990. [Abstract] [PDF]
International criteria for neuroblastoma diagnosis, staging, and response to treatment
MD Cohen
JCO Sep 1 1994: 1991–1993. [PDF]
Tamoxifen dosage and bioequivalence: a correction
AM Mondzac
JCO Sep 1 1994: 1993–1994. [PDF]
Lessons learned from measuring health-related quality of life in oncology
C Hurny and J Bernhard
JCO Sep 1 1994: 1994a. [PDF]
Tamoxifen and chemotherapy in the treatment of metastatic melanoma: are there other possible mechanisms explaining their potentiation?
G Gasparini
JCO Sep 1 1994: 1994b–1996. [PDF]
Cost-effective follow-up of breast cancer patients
JS Spratt
JCO Sep 1 1994: 1996a. [PDF]
It is now the age to define the appropriate follow-up of primary breast cancer patients
M Rosselli Del Turco, D Palli, and A Cariddi
JCO Sep 1 1994: 1996b–1997. [PDF]
"Salvage" therapy?
R Levin
JCO Sep 1 1994: 1997–1998. [PDF]
Primary therapy of Waldenstrom's macroglobulinemia with paclitaxel
MA Dimopoulos, R Luckett, and R Alexanian
JCO Sep 1 1994: 1998a. [PDF]
Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance
F Cowie and CR Pinkerton
JCO Sep 1 1994: 1998b–1999. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.